Breakthrough in Infant Food Allergy Research: Ready. Set. Food! Partners with ObvioHealth

Groundbreaking Partnership in Infant Allergy Research

In a significant advancement for the field of infant health, Ready. Set. Food!, a pioneer in early allergen introduction, has teamed up with ObvioHealth, a leader in digital clinical trial innovations. Together, they announced that they successfully recruited over 1,100 diverse participants for the Early Allergen System Experience (EASE) trial—two months ahead of schedule. This achievement marks a crucial milestone in their mission to enhance infant health outcomes and mitigate the financial burden associated with food allergies.

The EASE trial aims to investigate the benefits of early and consistent allergen exposure in infants, addressing common challenges faced by parents. These include sustaining allergen feeding practices and managing the related costs of introducing allergens. Utilizing ObvioHealth's cutting-edge ObvioGo® platform allowed the team to conduct this trial efficiently, reflecting real-world scenarios for families.

A Thoughtful Approach to Trial Design

"Ready. Set. Food! invested years into crafting this trial, emphasizing the importance of engaging participants through a decentralized approach,” said Sara Koors, the Executive Vice President of Research and Health Care Strategy at Ready. Set. Food!. The collaboration with ObvioHealth and 1nHealth made it possible to reach their recruitment targets significantly faster than anticipated. Now, they can work towards their goal of preventing life-threatening food allergies in babies while facilitating a better understanding of the practices that promote infant health.

Daniel Zakowski, the CEO of Ready. Set. Food!, expressed pride in the diversity of their participants. He noted that over 30% of the total enrollment consisted of individuals from minority or mixed-race backgrounds, mirroring the reality of their target consumer base. Such representation is indispensable in raising awareness that every infant deserves access to straightforward solutions that facilitate early allergen exposure in a manageable way.

Harnessing Digital Solutions for Recruitment

Launched in March 2024, the recruitment for the EASE trial was powered by ObvioHealth’s ObvioGo app, which utilized targeted digital strategies from 1nHealth. This technological approach provided efficient pre-screening, electronic consent (eConsent), and facilitated home-based participation. Consequently, these features eliminated logistical barriers, leading to a more user-friendly experience for families.

Moreover, 1nHealth's expertise in targeting effectively linked eligible participants through innovative campaigns, ensuring a recruitment process that was both efficient and reflective of real-life conditions. The expedited recruitment was a testament to the scalability of digital solutions in the realm of clinical trials.

What’s Next: Curavit’s Role in the Study

With the recruitment phase concluding successfully, Curavit Clinical Research will take charge of managing the EASE trial's next steps. As a Virtual Contract Research Organization (CRO), Curavit specializes in orchestrating decentralized clinical trials by integrating virtual sites with comprehensive CRO services. They will be responsible for overseeing safety protocols, ensuring regulatory compliance, and supervising the accurate execution of study protocols.

Additionally, Curavit will monitor the infant study population as they are introduced to the investigational food product, offering support to parents throughout the research process. The unwavering commitment of Ready. Set. Food!, ObvioHealth, and their collaborators is directed toward ensuring participant support as well as maintaining exceptional data integrity and quality throughout the trial.

Transforming Infant Health with Groundbreaking Research

As the EASE trial unfolds, the ObvioGo platform will play a fundamental role in collecting high-quality, real-world data and fostering participant engagement through user-friendly reporting tools. Ivan Jarry, CEO of ObvioHealth, remarked on the importance of maintaining robust data integrity, emphasizing that the research holds the potential to significantly improve infant health outcomes.

This ambitious collaboration is set to pave the way toward transformative advancements in addressing food allergies among infants, arguably one of the most pressing health challenges faced by families today. Ready. Set. Food!, ObvioHealth, and Curavit are poised to make a lasting impact on global health—ensuring all infants have the opportunity for a healthy start in life.